Antineoplastic agents and the associated myelosuppressive effects: A review

Journal of Pharmacy Practice

Volumn 27, Issue 5, 2014, Pages 440-446

  Barreto, Jason N ^a   McCullough, Kristen B ^a   Ice, Lauren L ^a   Smith, Judith A ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

anemia; antineoplastic agents; cancer; chemotherapy; hematology; myelosuppression; neutropenia; oncology; thrombocytopenia; toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DNA; FLUOROURACIL; GEMCITABINE; PACLITAXEL;

ADIPOSE TISSUE; ANEMIA; APOPTOSIS; BONE MARROW; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BURST FORMING UNIT; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; COLONY FORMING UNIT; DAUGHTER CELL; DNA REPLICATION; DNA SYNTHESIS; ERYTHROCYTE; EXTRAVASCULAR SPACE; FEEDBACK SYSTEM; GRANULOCYTE; HEMATOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC TISSUE; HUMAN; MACROPHAGE; MEGAKARYOCYTE; MICROENVIRONMENT; MYELINATED NERVE; NEUTROPENIA; NONHUMAN; NONMYELINATED NERVE; OVERALL SURVIVAL; PLURIPOTENT STEM CELL; PROGRESSION FREE SURVIVAL; REVIEW; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; CELL CYCLE; CHEMICALLY INDUCED; DRUG ADMINISTRATION ROUTE; DRUG EFFECTS; METABOLISM; NEOPLASMS;

ANTINEOPLASTIC AGENTS; BONE MARROW; CELL CYCLE; DRUG ADMINISTRATION ROUTES; ERYTHROCYTES; GRANULOCYTES; HEMATOPOIESIS; HUMANS; MEGAKARYOCYTES; NEOPLASMS; THROMBOCYTOPENIA;

EID: 84908893946     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190014546108     Document Type: Review

References (61)

1. Smith C. Hematopoietic stem cells and hematopoiesis. Cancer Control. 2003 ; 10 ((1)). 9-16
2. Portenoy RK, Itri LM. Cancer-related fatigue: guidelines for evaluation and management. Oncologist. 1999 ; 4 ((1)). 1-10
3. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966 ; 64 ((2)). 328-340
4. Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. 2001 ; 19 ((4)). 1137-1146
5. Fliedner TM, Graessle D, Paulsen C, Reimers K. Structure and function of bone marrow hemopoiesis: mechanisms of response to ionizing radiation exposure. Cancer Biother Radiopharm. 2002 ; 17 ((4)). 405-426
6. Gulati GL, Ashton JK, Hyun BH. Structure and function of the bone marrow and hematopoiesis. Hematol Oncol Clin North Am. 1988 ; 2 ((4)). 495-511
7. Hays K. Physiology of normal bone marrow. Semin Oncol Nurs. 1990 ; 6 ((1)). 3-8
8. Lohrmann HP, Schreml W. Cytotoxic drugs and the granulopoietic system. Recent Results Cancer Res. 1982 ; 81: 1-222
9. Travlos GS. Normal structure, function, and histology of the bone marrow. Toxicol Pathol. 2006 ; 34 ((5)). 548-565
10. Bain BJ, Clark DM, Wilkins B Bone marrow pathology. 4 th ed. Chichester, UK; Hoboken, NJ: Wiley-Blackwell; 2010. Chichester, UK; Hoboken, NJ: Wiley-Blackwell ; 2010:
11. Flemming W Zellsubstanz, Kern und Zelltheilung. Leipzig: F.C.W. Vogel ; 1882:
12. Hill BT, Baserga R. The cell cycle and its significance for cancer treatment. Cancer Treat Rev. 1975 ; 2 ((3)). 159-175
13. Chabner BA, Roberts TG. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer. 2005 ; 5 ((1)). 65-72
14. Ivanchuk SM, Rutka JT. The cell cycle: accelerators, brakes, and checkpoints. Neurosurgery. 2004 ; 54 ((3)). 692-699
15. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res. 2001 ; 7 ((8)). 2168-2181
16. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003 ; 36 ((3)). 131-149
17. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science. 1989 ; 246 ((4930)). 629-634
18. Vietti TJ, Valeriote FA. Conceptual basis for use of chemotherapeutic agents and their pharmacology. Pediatr Clin North Am. 1976 ; 23 ((1)). 67-92
19. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001 ; 411 ((6835)). 342-348
20. Fliedner TM. The role of blood stem cells in hematopoietic cell renewal. Stem Cells. 1998 ; 16 ((6)). 361-374
21. Tannock IF. Experimental chemotherapy and concepts related to the cell cycle. Int J Radiat Biol Relat Stud Phys Chem Med. 1986 ; 49 ((2)). 335-355
22. Parchment RE, Gordon M, Grieshaber CK, et al. Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Ann Oncol. 1998 ; 9 ((4)). 357-364
23. Risitano AM, Maciejewski JP, Selleri C, et al. Function and malfunction of hematopoietic stem cells in primary bone marrow failure syndromes. Curr Stem Cell Res Ther. 2007 ; 2 ((1)). 39-52
24. Shen Y, Nilsson SK. Bone, microenvironment and hematopoiesis. Curr Opin Hematol. 2012 ; 19 ((4)). 250-255
25. Walkley CR. Erythropoiesis, anemia and the bone marrow microenvironment. Int J Hematol. 2011 ; 93 ((1)). 10-13
26. Gordon MY. Physiology and function of the haemopoietic microenvironment. Br J Haematol. 1994 ; 86 ((2)). 241-243
27. Botnick LE, Hannon EC, Hellman S. Nature of the hemopoietic stem cell compartment and its proliferative potential. Blood Cells. 1979 ; 5 ((2)). 195-210
28. Hellman S, Reincke U, Botnick L, et al. Functional organization of the hematopoietic stem cell compartment: implications for cancer and its therapy. J Clin Oncol. 1983 ; 1 ((4)). 277-284
29. Snoeck HW. Aging of the hematopoietic system. Curr Opin Hematol. 2013 ; 20 ((4)). 355-361
30. Kane B. Cancer chemotherapy: teaching old drugs new tricks. Ann Intern Med. 2001 ; 135 ((12)). 1107-1110
31. Gale RP. Antineoplastic chemotherapy myelosuppression: mechanisms and new approaches. Exp Hematol. 1985 ; 13 ((suppl 16)). 3-7
32. Verschraegen CF, Natelson EA, Giovanella BC, et al. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs. 1998 ; 9 ((1)). 36-44
33. Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs. 2002 ; 62 ((suppl 1)). 1-15
34. Bennett CL, Djulbegovic B, Norris LB, et al. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013 ; 368 ((12)). 1131-1139
35. Tefferi A. Anemia in adults: a contemporary approach to diagnosis. Mayo Clin Proc. 2003 ; 78 ((10)). 1274-1280
36. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999 ; 91 ((19)). 1616-1634
37. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004 ; 40 ((15)). 2293-2306
38. Parameswaran R, Lunning M, Mantha S, et al. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer. 2014 ; 22 ((5)). 1217-1222
39. Connors T. Anticancer drug development: the way forward. Oncologist. 1996 ; 1 ((3)). 180-181
40. Gilani ST, Khan DA, Khan FA, et al. Adverse effects of low dose methotrexate in rheumatoid arthritis patients. J Coll Physicians Surg Pak. 2012 ; 22 ((2)). 101-104
41. Gutierrez-Urena S, Molina JF, Garcia CO, et al. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum. 1996 ; 39 ((2)). 272-276
42. Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003 ; 21 ((6)). 1044-1049
43. Rubenstein JL, Gupta NK, Mannis GN, et al. How I treat CNS lymphomas. Blood. 2013 ; 122 ((14)). 2318-2330
44. Skarin AT, Zuckerman KS, Pitman SW, et al. High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood. 1977 ; 50 ((6)). 1039-1047
45. Giai M, Biglia N, Sismondi P. Chemoresistance in breast tumors. Eur J Gynaecol Oncol. 1991 ; 12 ((5)). 359-373
46. Aschele C, Sobrero A, Faderan MA, et al. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res. 1992 ; 52 ((7)). 1855-1864
47. Vogelzang NJ. Continuous infusion chemotherapy: a critical review. J Clin Oncol. 1984 ; 2 ((11)). 1289-1304
48. Gardner SN. Cell cycle phase-specific chemotherapy: computational methods for guiding treatment. Cell Cycle. 2002 ; 1 ((6)). 369-374
49. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation. J Clin Oncol. 1997 ; 15 ((1)). 368-381
50. Meta-analysis Group In Cancer. J Clin Oncol. 1998 ; 16 ((1)). 301-308
51. Seifert P, Baker LH, Reed ML, et al. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer. 1975 ; 36 ((1)). 123-128
52. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-analysis group in cancer. J Clin Oncol. 1998 ; 16 ((11)). 3537-3541
53. DeWys WD, Goldin A, Man, El N. Hematopoietic recovery after large doses of cyclophosphamide: correlation of proliferative state with sensitivity. Cancer Res. 1970 ; 30 ((6)). 1692-1697
54. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 ; 374 ((9698)). 1331-1338
55. Bhuyan BK, Scheidt LG, Fraser TJ. Cell cycle phase specificity of antitumor agents. Cancer Res. 1972 ; 32 ((2)). 398-407
56. Minderman H, Linssen P, van der Lely N, et al. Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state. Leukemia. 1994 ; 8 ((3)). 382-387
57. Bergsagel DE, Robertson GL, Hasselback R. Effect of cyclophosphamide on advanced lung cancer and the hematological toxicity of large, intermittent intravenous doses. Can Med Assoc J. 1968 ; 98 ((11)). 532-538
58. Schein PS, Winokur SH. Immunosuppressive and cytotoxic chemotherapy: long-term complications. Ann Intern Med. 1975 ; 82 ((1)). 84-95
59. Trainor KJ, Seshadri RS, Morley AA. Residual marrow injury following cytotoxic drugs. Leuk Res. 1979 ; 3 ((4)). 205-210
60. Lohrmann HP. The problem of permanent bone marrow damage after cytotoxic drug treatment. Oncology. 1984 ; 41 ((3)). 180-184
61. Dale DC. Understanding neutropenia. Curr Opin Hematol. 2014 ; 21 ((1)). 1-2